Scientists
Come Together to Discover Possible Cures for Neurodegenerative Diseases
Released on
= August 30, 2005, 3:35 pm
Press Release
Author = GTCbio
Industry = Biotech
Press Release
Summary = GTCbio's conference on Therapeutic Strategies against
Neurodegenerative Conditions will be held October 10-11, 2005 at
the Boston Marriott Burlington. Over 30 speakers from academia,
industry and government organizations will present during this event.
Press Release
Body = MONROVIA - More than one million people suffer from neurodegenerative
conditions of the central nervous system in the United States alone.
Yet there are currently no cures and very few treatments for diseases
such as Parkinson's and Alzheimer's. On October 10 & 11, 2005,
over 30 speakers from
academia, industry and government organizations will come together
at GTCbio’s conference on Therapeutic Strategies against Neurodegenerative
Conditions with the common goal of discovering potential therapies
for such conditions.
<P>
Steven M. Paul, President of Lilly Research Laboratories and Vice
President of Eli Lilly & Company, will deliver one of two keynote
addresses. Paul has authored or co-authored more than 450 papers
and invited book chapters and serves on the editorial boards of
numerous scientific journals. He has been listed as one of the
most highly cited neuroscientists in the world (1980-2000) by the
I.S.I., Philadelphia, PA.
<P>
Delivering a keynote address on Day 2 entitled “Apoptosis
and Neurodegeneration: Death is in the Details” will be Dr.
Kevin A. Roth the Director of Neuropathology at the University of
Alabama at Birmingham. In addition to his research, clinical and
teaching responsibilities, Dr. Roth is an Associate Editor for the
American Journal of Pathology and the Journal of Histochemistry
and Cytochemistry. <P>
The conference will also feature presentations from Amgen, Bucks
Institute for Age Research, The Biologics Consulting Group, The
Burnham Institute, Columbia University, Curis Inc., Elan Pharmaceuticals,
Eli Lilly & Company, En Vivo Pharmaceuticals, GlaxoSmithKline,
Guilford Pharmaceuticals, Harvard Medical School,
Lundbeck, Memory Pharmaceuticals, Merck Research Laboratories, Neuroventures,
NIHM-NIH, NINDS-NIH, Oxford Bioscience Partners, Palmer & Dodge,
Pfizer Global Research, Recombinant Capital Inc., Rinat Neuroscience,
PsychoGenics Inc., Satori Pharmaceuticals Inc., University of North
Texas, University of Texas at Dallas,
University of Ottawa and Wyeth Research.
<P>
The event is presented by GTCbio and will take place at the Boston
Marriott Burlington in Burlington, Massachusetts. More information
including a detailed agenda, exhibitor opportunities and registration
information can be found at http://www.gtcbio.com/confpage.asp?cid
Web Site = http://www.gtcbio.com
Contact Details
= 434 W. Foothill Blvd.
Monrovia, CA 91016
626-256-6405
christy.bowman@gtcbio.com